Denis Cournoyer, MD
Primary Axis:
Cancer
Secondary Axis:
Medical Genetics and Genomics
Email:
Email contact form Research Focus:
Cancer gene therapy. hematopoietic chemoprotection. Gene therapy of hereditary disorders; gene targeting by homologous recombination.Gene therapy, retroviral vectors, drug resistance, chemoprotection, homologous recombination
External Website:
External Website Keywords:
Gene therapy, retroviral vectors, drug resistance, chemoprotection, homologous recombination
Location:
Montreal General Hospital Publications:
Cournoyer D, Toffelmire EB, Wells GA, Barber DL, Barrett BJ, Delage R, Forrest DL, Gagnon RF, Harvey EA, Laneuville P, Patterson BJ, Poon MC, Posen GA, Messner HA. Anti-erythropoietin antibody-mediated pure red cell aplasia following treatment with recombinant erythropoietin products: recommendations for minimization of risk. Journal of the American Society of Nephrology 2004; 15: 2728-2734.
Belenkov AI, Shenouda G, Rizhevskaya E, Cournoyer D, Belzile JP, Souhami L, Devic S, Terry Y, Chow K. Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin. Molecular Cancer Therapy 2004; 3:1525-1532.
Belzile JP, Karattzas A, Shiu HY, Létourneau S, Palerme JS, Cournoyer D. Increased resistance to nitrogen mustards and antifolates following in vitro selection of murine fibroblasts and primary hematopoietic cells cells transduced with a bicistronic retroviral vector expressing the rat glutathione S-transferase A3 and a mutant dihydrofolate reductase. Cancer Gene Therapy 2003; 10: 627-646.
